Otsuka's Guadecitabine Fails in ASTRAL-1 But AML Studies Continue

 
• By John Davis

Otsuka's guadecitabine has missed co-primary endpoints in older treatment-naïve AML patients but it continues to be evaluated in relapsed and refractory patients, in a therapeutic area undergoing considerable innovation.  

SC1808_Roller Coaster Road_350267387_1200.jpg
Drug development can be an up and down journey. • Source: Shutterstock

More from Clinical Trials

More from R&D